The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 20, 2017
Filed:
Mar. 16, 2012
Edward A. Botchwey, Iii, Charlottesville, VA (US);
Mary J. Laughlin, Crozet, VA (US);
Kevin R. Lynch, Charlottesville, VA (US);
Anusuya Das, Charlottesville, VA (US);
Anthony Awojoodu, Burtonsville, MD (US);
Edward A. Botchwey, III, Charlottesville, VA (US);
Mary J. Laughlin, Crozet, VA (US);
Kevin R. Lynch, Charlottesville, VA (US);
Anusuya Das, Charlottesville, VA (US);
Anthony Awojoodu, Burtonsville, MD (US);
University of Virginia Patent Foundation, Charlottesville, VA (US);
Abstract
The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P/S1Pactivation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1Pexpression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1Pand CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand. The results show that S1P is a very powerful role player in pharmacological marrow-derived stem cell mobilization and recruitment.